IMB Dx, Inc. (KOSDAQ:461030)
4,135.00
-110.00 (-2.59%)
Jun 10, 2026, 3:30 PM KST
IMB Dx Revenue
IMB Dx had revenue of 1.27B KRW in the quarter ending March 31, 2026, with 27.06% growth. This brings the company's revenue in the last twelve months to 5.60B, up 59.65% year-over-year. In the year 2025, IMB Dx had annual revenue of 5.33B with 56.40% growth.
Revenue (ttm)
5.60B
Revenue Growth
+59.65%
P/S Ratio
10.63
Revenue / Employee
n/a
Employees
n/a
Market Cap
59.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.33B | 1.92B | 56.40% |
| Dec 31, 2024 | 3.41B | -619.97M | -15.40% |
| Dec 31, 2023 | 4.03B | 1.40B | 53.42% |
| Dec 31, 2022 | 2.62B | 1.39B | 113.34% |
| Dec 31, 2021 | 1.23B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 199.60B |
| ORIENT BIO | 59.09B |
| Amicogen | 43.44B |
| CG Invites | 29.22B |
| GeneOne Life Science | 17.12B |
| Prestige BioPharma | 16.21B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.79B |